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prophylaxis with fondaparinux is cost-effective was addressed in
this study. METHODS: A decision analytic model was developed
to compare a four-week fondaparinux regimen with a one-week
regimen. Clinical input parameters were derived from clinical
trials and other published sources. Cost data for Swiss univer-
sity hospitals were obtained from the single service tariffs data-
base (Tarmed), the Swiss Drugs Compendium and the diagnosis
related groups database (AP-DRG) and were expressed in 2004
Swiss francs (CHF). The model simulates a cohort of HFS and
THR patients over 30 days and 5 years. Outcomes were mea-
sured in life-years gained (LYG). Future costs and outcomes were
discounted with an annual rate of four percent. RESULTS: In a
hypothetical cohort of 1000 HFS patients, extended prophylaxis
avoids 10 fatal events and 9 VTEs over a time horizon of 30
days. The corresponding ICER is CHF 2801 per LYG. With a
lower baseline risk for VTE in THR patients, extended fonda-
parinux prophylaxis prevents one fatal event in 1000 patients
over a time horizon of 30 days, yielding an ICER of CHF20,294
per LYG. After ﬁve years, extended prophylaxis is cost saving in
both HFS and THR patients. The model results were robust to
variations of major clinical and cost parameters. CONCLU-
SIONS: Extended prophylaxis with fondaparinux in THR and
HFS patients is cost-effective from a Swiss health care perspec-
tive using a time horizon of 30 days. With a longer time horizon
of ﬁve years, extended prophylaxis with fondaparinux is 
cost-saving.
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OBJECTIVE: To determine the cost-effectiveness of fonda-
parinux compared with enoxaparin for extended prophylaxis
against venous thromboembolism in patients undergoing hip
fracture surgery using Dutch estimates of costs. METHODS:
Costs and effects are modeled using a cohort simulation model.
Short term transition probabilities (until day 30) are based from
placebo controlled trials. Long term probabilities are obtained
from the literature. Resource use and costs were obtained from
a Dutch costing study concerning bleedings and symptomatic
events. Outcome measures were rates of symptomatic throm-
boembolic events, deaths avoided and health care costs. Costs
were in 2003 values. “Conﬁdence intervals” (CI) are obtained
by probabilistic sensitivity analysis. RESULTS: Fondaparinux
was estimated to prevent an additional 158 symptomatic venous
thromboembolic events (per 10,000 patients) at 1 year after
major orthopaedic surgery compared with enoxaparin (95%
CI:163–371). The cost savings (per patient) of using fonda-
parinux over enoxaparin are estimated at €103 (€34–€178). The
number of deaths avoided (per 10,000 patients) is estimated at
103 (57–165). The probability that fondaparinux is both more
effective and cost saving is estimated at 0.9996. CONCLUSION:
Extended prophylaxis with fondaparinux after major orthope-
dic surgery can be expected to result in both better outcomes and
cost savings when compared with extended prophylaxis with
enoxaparin.
PCV91
COST EFFECTIVENESS OF EXTENDED PROPHYLAXIS WITH
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OBJECTIVE: To determine the cost effectiveness of extended
prophylaxis with fondaparinux to prevent venous thromboem-
bolism in patients undergoing hip fracture surgery compared to
short term using UK and Dutch estimates of costs. METHODS:
Costs and effects are modeled using a cohort simulation model.
Short term transition probabilities (until day 30) are obtained
from placebo controlled trials. Long term probabilities are
obtained from the literature. UK resource use and costs were
obtained from a published analysis concerning short term 
prophylaxis. Dutch resource use and costs were estimated in a
separate costing study concerning bleedings and symptomatic
events. Outcome measures were rates of symptomatic throm-
boembolic events, deaths avoided and health care costs. Costs
were in 2004 values. “Conﬁdence intervals” (CI) were obtained
by probabilistic sensitivity analysis. RESULTS: At one year
extending prophylaxis with fondaparinux after major
orthopaedic surgery from 7 to 22 days was estimated to prevent
343 symptomatic venous thromboembolic events (per 10,000
patients) (95% CI:283–391). The additional cost (per patient) of
extending the prophylactic period is estimated at £164
(£117–£212) in the UK and at €66 in The Netherlands. The
number of deaths avoided (per 10,000 patients) is estimated at
138 (89–192). Costs per symptomatic VTE avoided are esti-
mated at £4,788 (£3258–£6906) in the UK and at €1915
(€392–€4021) in The Netherlands. Costs per death avoided 
are estimated at £11,932 (£7220–£20,480) and €4773
(€892–€11,629). When assuming the average survival after
surgery at 6 years, costs per life year gained are estimated at
under £3,000 for the UK and at under €900 for The Nether-
lands. CONCLUSION: Our estimates indicate that extending
the prophylaxis with fondaparinux from 7 to 21 days has an
acceptable balance between cost and outcomes both in the UK
and The Netherlands.
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Oral anticoagulation is indicated for a number of conditions,
including prevention of systemic embolism in patients with
mechanical heart valves, valvular heart disease, myocardial
infarction and atrial ﬁbrillation. VKA are frequently prescribed
as long term treatment. Due to the features of treatment, VKA
have the potential to cause dissatisfaction and reduce QoL.
OBJECTIVES: To assess Health- Related Quality of life
(HRQOL) in patients receiving VKA comparing their health
status with matched controls. METHODS. Ninety-two consec-
utive patients receiving VKA (53 male; age range 37–81 years)
were enrolled among those followed by our anticoagulation
clinic. The more frequent indications for VKA treatment were
atrial ﬁbrillation and venous thromboembolism. Each patient
was matched by age and sex with one control from a database
of a population based naturalistic prospective survey. The
EuroQoL, completed during the enrolment visit, was used to
evaluate HRQOL. To evaluate differences in the ﬁve dimensions
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between the two groups was used Chi Square Test. To evaluate
differences in EQ VAS was used both Paired sample T test and
a regression analysis using bootstrap estimated of standard error.
RESULTS: No statistically signiﬁcant differences were reported
in all dimensions between the two groups: mobility (P = 1.000),
self care (P = 0.064), usual activities (P = 0.213), pain/discom-
fort (P = 0.213) and anxiety/depression (P = 0.512). The ﬁgures
obtained using VAS to assess the global health status was: 72.8
(SD, ± 19.7) in patients treated with VKA and 73.9 (SD, ± 16.0)
in matched controls; this difference was not statistically signiﬁ-
cant (p = 0.708 Paired sample T); also bootstrap conﬁdent 
intervals indicated that there was no statistically signiﬁcant 
differences between the two groups. CONCLUSIONS: Even if it
is conceivable that different settings would give different results,
our study show that in patients on oral anticoagulant treatment
the overall perception of health status was not signiﬁcantly dif-
ferent from that of matched controls.
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OBJECTIVE: Wide use of disease-oriented quality of life (QoL)
measures, that are not preference based, and thus lack legitimacy
for direct use in economic evaluations, has prompted a need for
modeling to derive utilities. The QoL Assessment of Growth
Hormone Deﬁciency in Adults questionnaire (QoL-AGHDA) is
a disease-oriented measure used to assess impairment in QoL in
adults with growth hormone deﬁciency. The present study aims
to provide a model for deriving utilities directly from the QoL-
AGHDA. METHODS: The EQ-5D and the QoL-AGHDA were
mailed to a random sample (n = 2990) of the Swedish popula-
tion (response rate, 65%). The Jack knife method was used to
obtain cross-validated parameters of QoL-AGHDA-based utili-
ties. Using the EQ-5Dindex (derived from European values) as the
dependent variable, and age, gender and QoL-AGHDA score as
independent variables in repeated regression analyses, each time
omitting one tenth of the sample (the Jack-knife method) esti-
mates for the coefﬁcients for transformation of the QoL-
AGHDA into a single score (range, 0–1) were achieved. These
transformed QoL-AGHDA scores correspond to the QoL-
AGHDA-based utility. RESULTS: The transformation algorithm
was: U (QoL-AGHDA-based utilities) = [102.2 - 1.80*QoL-
AGHDA score - 0.227 * age - 1.21*Gender (men = 0; women
= 1)]/100. The mean of the weighted estimate for the total pop-
ulation (n = 1752) was 0.83 (SD, 0.09). The estimate for men (n
= 861; mean, 0.84; SD, 0.09) was higher (p < 0.001) than for
women (n = 891; mean, 0.82; SD, 0.09). CONCLUSION: The
present model could be used to derive utilities directly from the
QoL-AGHDA; however, it should be highlighted that the coefﬁ-
cients presented here come from the homogeneous Swedish pop-
ulation and thus application to other populations should be
carefully considered.
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Although the beneﬁcial effect of growth hormone replacement
on QoL in adults with GHD is well recognized, the long-term
effect of this therapy on QoL remains uncertain. OBJECTIVES:
To determine the effect of long term GH replacement on QoL in
patients compared with country-speciﬁc normative data for the
general population (GP). METHODS: QoL was measured using
Quality of Life Assessment for Growth Hormone Deﬁciency in
Adults (QoL-AGHDA) in patients and GP in Sweden and
England & Wales (E&W). QoL-AGHDA is a 25-item question-
naire that elicits yes/no responses that are used to compute a
summary score. GP data were obtained from 1682 randomly
selected individuals from Sweden and 892 from E&W. These
data were compared with KIMS (Pﬁzer International Metabolic
Database) data for 121 patients from Sweden and 77 from E&W
with 5 years of complete follow-up. Age-range was 20–79 years.
Linear regression methods were used to estimate age- and
gender-adjusted differences between patients and the GP at one-
year intervals. The signiﬁcance level was set at 5%. RESULTS:
The (adjusted to age 50) mean QoL-AGHDA score at baseline
were 8.21 and 15.2 (SEM 0.44 and 0.68) for the Swedish and
E&W patients, respectively. For the GP samples the corre-
sponding mean scores were 3.80 and 6.6 (SEM 0.12 and 0.20).
The mean difference between patient scores at baseline and GP
scores were -4.4 for Sweden and -8.6 for E&W (p < 0.0001).
However, these differences reduced markedly over the ﬁrst year
of treatment and were subsequently maintained at statistically
non-signiﬁcant differences compared to the general populations.
CONCLUSIONS: This study shows that adults with GHD who
receive long-term GH replacement beneﬁt most with respect to
QoL during the ﬁrst 12 months of therapy and that this improve-
ment was maintained at levels close to normalization in QoL
over 5 years of follow up.
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OBJECTIVES: To evaluate the impact of acromegaly on health-
related quality of life (HRQOL) in European patients treated
with Sandostatin® LAR®. The secondary objectives were to
investigate the correlation between HRQOL and subpopulations
based on exploratory variables [sociodemographic and disease-
